19 June 2020: any MRCA Treatment Pathway 1 and Treatment Pathway 2 information below has been retained for historical purposes only. A Single Treatment Pathway has been in effect since 12 December 2019. See section 8.1 Overview [2] for current information.
Determination of claims for liability and compensation (including treatment) are made in accordance with section 333 [3] of the MRCA. In relation to treatment this means any decision pursuant to paragraph 271(1)(c), 271(2)(c), 272(b) and 273(c) that treatment was reasonable in the circumstances. The delegation for section 333 [3] is at the APS 5 level and above.
A — PS 3 level delegates and above are able to determine the amount of compensation payable for Pathway 1 treatment pursuant to section 276(1) [4].
Further information on delegations is contained at paragraph 1.3 in Chapter 1 [5] of this manual.
Links
[1] https://clik.dva.gov.au/user/login?destination=comment/reply/19265%23comment-form
[2] http://auth-clik.dvastaff.dva.gov.au/military-compensation-mrca-manuals-and-resources-library/policy-manual/ch-8-treatment-injuries-and-diseases/81-overview
[3] clik://LEGIS/MRC-ACTS/MRCA/S333
[4] clik://LEGIS/MRC-ACTS/MRCA/S276
[5] https://clik.dva.gov.au/military-compensation-mrca-manuals-and-resources-library/policy-manual/ch-1-introduction